艾曲泊帕引发血栓栓塞的风险：一例深静脉血栓形成和双侧肺栓塞的病例报告
Risk of Thromboembolism With Eltrombopag: A Case Report of Deep Vein Thrombosis and Bilateral Pulmonary Embolism.
作者信息
Ghumman Ghulam Mujtaba, Fatima Huda, Singh Gunbir, Khalid Taha, Ayoubi Mohamed
机构信息
Internal Medicine, St. Vincent Mercy Medical Center, Toledo, USA.
Internal Medicine, MedStar Union Memorial Hospital, Baltimore, USA.
出版信息
Cureus. 2023 Jan 10;15(1):e33615. doi: 10.7759/cureus.33615. eCollection 2023 Jan.
Abstract
Eltrombopag is a second-line therapy for refractory thrombocytopenia from immune thrombocytopenic purpura (ITP). The medication is generally well tolerated but can lead to adverse thromboembolic complications in rare instances. We present a case of lower extremity deep vein thrombosis with bilateral pulmonary embolism in an ITP patient receiving eltrombopag. The patient underwent catheter-directed thrombolysis for pulmonary embolism. Eltrombopag was stopped on discharge, considering the potential cause of venous thrombosis.
摘要
艾曲泊帕是治疗免疫性血小板减少性紫癜（ITP）所致难治性血小板减少症的二线疗法。该药物一般耐受性良好，但在罕见情况下可导致不良血栓栓塞并发症。我们报告一例接受艾曲泊帕治疗的ITP患者发生下肢深静脉血栓形成并伴有双侧肺栓塞的病例。该患者接受了针对肺栓塞的导管定向溶栓治疗。考虑到静脉血栓形成的潜在原因，患者出院时停用了艾曲泊帕。
相似文献
1
Risk of Thromboembolism With Eltrombopag: A Case Report of Deep Vein Thrombosis and Bilateral Pulmonary Embolism.艾曲泊帕引发血栓栓塞的风险：一例深静脉血栓形成和双侧肺栓塞的病例报告
Cureus. 2023 Jan 10;15(1):e33615. doi: 10.7759/cureus.33615. eCollection 2023 Jan.
2
Portal vein thrombosis during eltrombopag treatment for immune thrombocytopenic purpura in a patient with liver cirrhosis due to hepatitis C viral infection.丙型肝炎病毒感染所致肝硬化患者在接受艾曲泊帕治疗免疫性血小板减少性紫癜期间发生门静脉血栓形成。
J Clin Exp Hematop. 2013;53(2):151-5. doi: 10.3960/jslrt.53.151.
3
Eltrombopag-related renal vein thromboembolism in a patient with immune thrombocytopenia: A case report.一名免疫性血小板减少症患者出现与艾曲泊帕相关的肾静脉血栓栓塞：病例报告
World J Clin Cases. 2021 Apr 16;9(11):2611-2618. doi: 10.12998/wjcc.v9.i11.2611.
4
Severe Portal Vein Thrombosis During Eltrombopag Treatment Concomitant Splenectomy for Immune Thrombocytopenia.艾曲泊帕治疗免疫性血小板减少症并同期脾切除术中发生的严重门静脉血栓形成
Cureus. 2021 Aug 27;13(8):e17478. doi: 10.7759/cureus.17478. eCollection 2021 Aug.
5
Eltrombopag for the treatment of chronic idiopathic (immune) thrombocytopenic purpura (ITP).艾曲波帕治疗慢性特发性（免疫性）血小板减少性紫癜（ITP）。
Health Technol Assess. 2011 May;15 Suppl 1:23-32. doi: 10.3310/hta15suppl1/03.
6
Eltrombopag as second line treatment in patients with primary immune thrombocytopenia: A single center real life experience.依鲁替尼治疗原发免疫性血小板减少症：单中心真实世界经验。
Blood Cells Mol Dis. 2021 Dec;92:102620. doi: 10.1016/j.bcmd.2021.102620. Epub 2021 Oct 21.
7
Successful eltrombopag treatment of severe refractory thrombocytopenia in chronic myelomonocytic leukemia: Two cases reports: A CARE-compliant article.艾曲泊帕成功治疗慢性粒单核细胞白血病严重难治性血小板减少症：两例报告：一篇遵循CARE原则的文章
Medicine (Baltimore). 2017 Oct;96(43):e8337. doi: 10.1097/MD.0000000000008337.
8
Spotlight on eltrombopag in treatment-refractory chronic primary immune thrombocytopenia.聚焦于难治性慢性原发性免疫性血小板减少症的艾曲泊帕治疗。
BioDrugs. 2011 Dec 1;25(6):401-4. doi: 10.2165/11207620-000000000-00000.
9
Eltrombopag: a review of its use in treatment-refractory chronic primary immune thrombocytopenia.依洛尤单抗：治疗抵抗性慢性原发免疫性血小板减少症的治疗药物。
Drugs. 2011 Jul 9;71(10):1333-53. doi: 10.2165/11207390-000000000-00000.
10
The Association Between PICC Use and Venous Thromboembolism in Upper and Lower Extremities.经外周静脉穿刺中心静脉置管（PICC）与上下肢静脉血栓栓塞的关联。
Am J Med. 2015 Sep;128(9):986-93.e1. doi: 10.1016/j.amjmed.2015.03.028. Epub 2015 May 1.
引用本文的文献
1
Treatment of Acute Ischaemic Stroke and Concomitant Multiple Arterial Splanchnic Thromboses in a Patient with Immune Thrombocytopenia on Thrombopoietin Agonist: A Case Report.血小板生成素激动剂治疗免疫性血小板减少症患者的急性缺血性中风及合并多发内脏动脉血栓形成：一例报告
Neurol Int. 2023 Sep 18;15(3):1191-1199. doi: 10.3390/neurolint15030074.
2
Long term use of eltrombopag in children with chronic immune thrombocytopenia: extended real life retrospective multicenter experience of the Italian Association of Pediatric Hematology and Oncology.艾曲泊帕在儿童慢性免疫性血小板减少症中的长期应用：意大利儿科血液学和肿瘤学协会的真实生活扩展回顾性多中心经验
Front Med (Lausanne). 2023 Jul 14;10:1214308. doi: 10.3389/fmed.2023.1214308. eCollection 2023.
本文引用的文献
1
Optimal use of thrombopoietin receptor agonists in immune thrombocytopenia.血小板生成素受体激动剂在免疫性血小板减少症中的优化应用。
Ther Adv Hematol. 2019 Apr 11;10:2040620719841735. doi: 10.1177/2040620719841735. eCollection 2019.
2
Platelet Apoptosis and PAI-1 are Involved in the Pro-Coagulant State of Immune Thrombocytopaenia Patients Treated with Thrombopoietin Receptor Agonists.血小板凋亡和 PAI-1 参与了用血小板生成素受体激动剂治疗的免疫性血小板减少症患者的促凝状态。
Thromb Haemost. 2019 Apr;119(4):645-659. doi: 10.1055/s-0039-1678706. Epub 2019 Feb 11.
3
Safety and efficacy of long-term treatment of chronic/persistent ITP with eltrombopag: final results of the EXTEND study.依曲泊帕治疗慢性/持续性 ITP 的长期安全性和疗效：EXTEND 研究的最终结果。
Blood. 2017 Dec 7;130(23):2527-2536. doi: 10.1182/blood-2017-04-748707. Epub 2017 Oct 17.
4
Eltrombopag Induced Thrombosis: A Case with Acute Myocardial Infarction.艾曲泊帕诱发的血栓形成：一例急性心肌梗死病例
Curr Drug Saf. 2016;11(2):174-6. doi: 10.2174/1574886311207040255.
5
Is ITP a thrombophilic disorder?ITP 是否为血栓形成倾向疾病？
Am J Hematol. 2016 Jan;91(1):39-45. doi: 10.1002/ajh.24234. Epub 2015 Nov 26.
6
Signal for Thrombosis with Eltrombopag and Romiplostim: A Disproportionality Analysis of Spontaneous Reports Within VigiBase®.艾曲泊帕和罗米司亭引发血栓形成的信号：基于VigiBase®中自发报告的不成比例性分析
Drug Saf. 2015 Dec;38(12):1179-86. doi: 10.1007/s40264-015-0337-1.
7
Two cases of thrombosis in patients with antiphospholipid antibodies during treatment of immune thrombocytopenia with romiplostim, a thrombopoietin receptor agonist.两例抗磷脂抗体患者在使用促血小板生成素受体激动剂罗米司亭治疗免疫性血小板减少症期间发生血栓形成的病例。
Semin Arthritis Rheum. 2016 Feb;45(4):e10-2. doi: 10.1016/j.semarthrit.2015.07.008. Epub 2015 Jul 29.
8
Efficacy and safety of eltrombopag in treatment-refractory primary immune thrombocytopenia: a retrospective study.艾曲泊帕治疗难治性原发性免疫性血小板减少症的疗效与安全性：一项回顾性研究。
Blood Coagul Fibrinolysis. 2016 Jan;27(1):47-52. doi: 10.1097/MBC.0000000000000380.
9
Risk of thromboembolism with thrombopoietin receptor agonists in adult patients with thrombocytopenia: Systematic review and meta-analysis of randomized controlled trials.血小板生成素受体激动剂治疗成人血小板减少症患者的血栓栓塞风险：随机对照试验的系统评价和荟萃分析
Med Clin (Barc). 2015 Dec 21;145(12):511-9. doi: 10.1016/j.medcli.2015.03.014. Epub 2015 Jun 4.
10
Thrombotic risk in patients with primary immune thrombocytopenia is only mildly increased and explained by personal and treatment-related risk factors.原发性免疫性血小板减少症患者的血栓风险仅轻度增加，可归因于个人和治疗相关的风险因素。
J Thromb Haemost. 2014 Aug;12(8):1266-73. doi: 10.1111/jth.12636. Epub 2014 Jul 16.
Zotero 插件